AI Article Synopsis
- Sarcomatoid renal cell carcinoma has a generally poor prognosis, with most patients surviving less than a year.
- An 83-year-old male presented with neurological symptoms; imaging revealed a mass in the right temporal lobe.
- He underwent cytoreductive surgery, and despite tumor recurrence, he has survived nearly four years, highlighting that combined treatment approaches can improve outcomes for elderly patients.
Article Abstract
Sarcomatoid renal cell carcinoma typically signifies an exceptionally poor prognosis, with patients rarely surviving beyond one year. An 83-year-old male presented to our hospital with complaints of headache and left-sided limb weakness. Computed tomography (CT) scans of the head and lungs disclosed a mass within the right temporal lobe, accompanied by peritumoral edema in the right cerebral hemisphere. Brain magnetic resonance imaging (MRI) with contrast enhancement and diffusion-weighted imaging (DWI) delineated a mass in the right temporal lobe, measuring 3 × 3 × 3 cm. He underwent cytoreductive surgery successively in the neurosurgery and urology departments. Despite experiencing postoperative tumour recurrence, the patient has lived close to four years to date. This case report illustrates that cytoreductive surgery combined with systemic pharmacotherapy can still confer significant survival benefits for elderly patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12968/hmed.2024.0300 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Aggressive mucinous tubular and spindle cell carcinoma of the kidney: a clinicopathological and genetic analysis of four cases].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing100191, China.
To understand the clinicopathological and molecular genetic characteristics of aggressive renal mucinous tubular and spindle cell carcinoma (MTSCC). The clinical features, histology, immunophenotype, molecular characteristics and prognosis of 4 cases of metastatic/recurrent renal MTSCC that were submitted to the Peking University Third Hospital (2 cases), Institute of Urology, Peking University (one case) and Zhejiang Provincial People's Hospital (one case) from 2015 to 2020 were retrospectively reviewed and analyzed. Among the four patients, two were male and two were female.
View Article and Find Full Text PDFTrends and Outcomes in Sarcomatoid Renal Cell Carcinoma: Analysis of the National Cancer Data Base.
Eur Urol Open Sci
January 2025
Department of Urology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Background And Objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.
Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC.
Unclassifiable Renal Cell Carcinoma With an Estimated 100% Sarcomatoid Component: A Case Report.
Cureus
December 2024
Department of Anatomopathology, Mohammed VI University Hospital/Faculty of Medicine, Mohammed 1st University, Oujda, MAR.
Sarcomatoid renal cell carcinoma (RCC) is an aggressive tumour with a poor prognosis. It is not a distinct histological entity, as it can be found in any subtype of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic treatment.
View Article and Find Full Text PDFCutaneous Metastasis of Bladder Cancer: A Systematic Review.
Cureus
November 2024
Department of Obstetrics and Gynecology, Beaumont Hospital, Dearborn, USA.
Bladder cancer is one of the main causes of urogenital cancer (30-35% of the total urological cancers). Although metastases from urologic tumors are rare, it is associated with a high mortality rate. The location and pattern of metastasis are random and unpredictable.
View Article and Find Full Text PDFCase 332: Tyrosine Kinase Inhibitor-induced Intestinal Lymphangiectasia.
Radiology
December 2024
From the Department of Radiology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054.
History A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrectomy developed recurrent disease adjacent to the inferior vena cava. The patient underwent surveillance imaging 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after completing a 2-month regimen of palliative stereotactic body radiation therapy to the right nephrectomy bed and site of recurrence. (Stereotactic body radiation therapy was initiated 5 months after pazopanib treatment was initiated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!